AIM
AIM ImmunoTech Inc.
stockNYSEAMERICAN
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.16 | 2026-10-14 | +6.27% | 1.472 |
| 1M | 0.21 | 2026-09-21 | -17.92% | 1.532 |
| 3M | 0.25 | 2026-07-21 | -30.94% | 0.778 |
| 6M | 0.49 | 2026-04-21 | -64.76% | -0.126 |
| 1Y | 2.61 | 2025-10-21 | -93.41% | 0.404 |
| 2Y | 0.26 | 2024-10-21 | -35.02% | — |
| 5Y | 1.93 | 2021-10-21 | -91.08% | -6.612 |
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) stock price today is $0.17, and today's volume is 131,591. AIM is up 3.460% today. The 30 day average volume is 1.88M. AIM market cap is $6.86M with 39.89M shares outstanding.